Immunotherapy for ATL using specific chimeric antigen receptor

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461427
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Hematology
• Research Institution: Kagoshima University
• Principal Investigator: Yoshimitsu Makoto 鹿児島大学, 医歯学域医学系, 准教授 (70404530)
• Co-Investigator(Kenkyū-buntansha): ITOH Yuji 鹿児島大学, 理工学域理学系, 教授 (60223195)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: CART療法 / T細胞受容体

Outline of Final Research Achievements

Adult T cell lekukemia/lymphoma is a retractable hematological malignancy, which requires effective therapeutic modality. It is very important for immunotherapy using chimeric antigen receptor T cell to identify therapeutically relevant target antigen. Here we assessed T cell receptor repertoire among patients with ATL. We found that T cell receptor V beta 2 was the most prevalent TCR, more than 15% of ATL patients express TCRVb2. After cloning of TCRVb2 by RACE, we developed TCRVb2 expressing lentiviral vector and establish TCRVb2 highly expressing cell line. We tried to identify anti-TCRVb2 specific antibody by phage display library. Further optimization of this protocol need to be explored.

Free Research Field

血液内科